WallStSmart

BP PLC ADR (BP)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BP PLC ADR generates 2992% more annual revenue ($187.64B vs $6.07B). EW leads profitability with a 17.7% profit margin vs 0.0%. BP appears more attractively valued with a PEG of 0.18. EW earns a higher WallStSmart Score of 55/100 (C).

BP

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 4.5Value: 4.7Quality: 5.0

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPSignificantly Overvalued (-4001.1%)

Margin of Safety

-4001.1%

Fair Value

$0.94

Current Price

$44.79

$43.85 premium

UndervaluedFair: $0.94Overvalued
EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP3 strengths · Avg: 9.0/10
PEG RatioValuation
0.1810/10

Growing faster than its price suggests

Market CapQuality
$114.71B9/10

Large-cap with strong market position

Free Cash FlowQuality
$4.14B8/10

Generating 4.1B in free cash flow

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

BP4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Return on EquityProfitability
1.7%3/10

ROE of 1.7% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, Market Cap, Free Cash Flow. PEG of 0.18 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : BP

The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2239.0x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Key Dynamics to Monitor

BP profiles as a value stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

BP generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 54/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?